# A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

> **NCT01333540** · PHASE2 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 69 (actual)

## Conditions studied

- Opioid-induced Constipation (OIC)

## Interventions

- **DRUG:** TD-1211
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01333540
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-05
- **Final completion:** 2012-06
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333540, "A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01333540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*